HilleVax(HLVX) - 2024 Q4 - Annual Results

Exhibit 99.1 HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives Net loss for the fourth quarter 2024 was $33.9 million and $147.3 for the year ended December 31, 2024, compared to $37.0 mi ...